Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

PSMA-targeted Docetaxel Nanoparticles BIND-014

Known as: BIND-014 
A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane… 
National Institutes of Health

Related topics

Related topics

2 relations
Microtubule ProcessNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
In 1995, the year the first cancer nanomedicine, Doxil, was approved by the Food and Drug Administration (FDA), only 23… 
Review
2018
Review
2018
PLGA-Based Nanoparticles in Cancer Treatment
Nanomedicines can be used for a variety of cancer therapies including tumor-targeted drug delivery, hyperthermia, and… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2018
Highly Cited
2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial
Importance Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)–targeted nanoparticles is… 
  • table 1
  • table 2
  • figure 2
  • figure 1
  • figure 3
Highly Cited
2016
Highly Cited
2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel… 
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Review
2015
Review
2015
Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects
Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical… 
Review
2014
Review
2014
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2014
Review
2014
Targeted therapy using nanotechnology: focus on cancer
Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as… 
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Review
2012
Review
2012
Docetaxel Nanotechnology in Anticancer Therapy
Taxanes have been recognized as a family of very efficient anticancer drugs, but the formulation in use for the two main taxanes… 
Highly Cited
2012
Highly Cited
2012
First plant-made biologic approved
  • J. Fox
  • Nature Biotechnology
  • 2012
  • Corpus ID: 30936119
The US Food and Drug Administration in May approved Elelyso (taliglucerase alfa), an enzyme produced in genetically engineered… 
Review
2011
Review
2011
Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
Nanoparticles (NPs) have become an important tool in many industries including healthcare. The use of NPs for drug delivery and… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE